HLA Class I and Class II Antigen Expression on Squamous Cell Carcinoma of the Head and Neck

Houck, J. R.; Sexton, F. Mack; Zajdel, Grazyna

doi:10.1001/archotol.1990.01870100075016

Cited by 31 publications

(18 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although a lower frequency of loss of W6/32 positivity was found in this study compared with previous studies on HNSCC and HLA class I expression (Esteban et al, 1989;Houck et al, 1990;Mattijsen et al, 1991), which may be accounted for by differences in the tumour samples used, the high frequency of aberrant allelic expression detected implies that previous studies on HLA class I expression using antibodies directed against monomorphic determinants of these molecules may be underestimates. Using an even wider panel of antibodies against these allele-specific determinants, greater amounts of aberrant expression may be detected.…”

Section: Discussioncontrasting

confidence: 98%

“…Other studies on HLA-DR expression in HNSCC give varying figures, ranging from as low as 8% (Esteban et al, 1989) to as high as 70% (Houck et al, 1990;Mattijssen et al, 1991). Previous reports have also differed as to what type of tumour predominantly express HLA class II molecules, with Esteban et al (1989) correlating HLA-DR expression to well-differentiated tumours but with others stating that class II positivity was associated mainly with poorly differentiated tumours (Houck et al, 1990;Mattijssen et al, 1991). In this study, although no correlations could be made regarding HLA-DR positivity with site, stage and regional lymph node involvement, it was observed that a high frequency of well-differentiated tumours showed de novo expression of HLA-DR compared with moderately/poorly differentiated HNSCC.…”

Section: Discussionmentioning

confidence: 98%

“…Previous studies on HLA expression in HNSCC (Esteban et al, 1989;Houck et al, 1990;Mattijsen et al, 1991) …”

mentioning

confidence: 99%

See 2 more Smart Citations

An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma

Vora

Rodgers²,

Aj³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

Summary For the presentation of peptide antigens to cytotoxic CD8+ T lymphocytes of the immune system, the expression of human leukocyte antigen (HLA) class I molecules on the cell surface is necessary. There is increasing evidence that surface HLA class antigen expression is altered in a variety of human tumours by either loss or down-regulation of these molecules, which may be a strategy for evasion of immunosurveillance by malignant cells. This study has examined the expression of HLA class molecules in head and neck squamous cell carcinoma (HNSCC) specimens by immunohistochemistry, using a wide panel of antibodies directed against allele-specific as well as monomorphic determinants of these molecules. The expression of TAP proteins, HLA-DR and the co-stimulatory molecule ICAM-1 were also studied. In addition, the expression of the tumour-associated antigens (TAA) p53 and MAGE genes was determined. Aberrant allelic expression of HLA class antigens was detected in 17 out of 34 (50%) of the specimens stained, whereas HLA class I expression determined by W6/32 staining was found to be heterogeneous in only 2 out of 34 (6%) cases. Decreased expression of ICAM-1 was observed in 12 out of 34 (35%) tumour specimens and de novo expression of HLA-DR (HLA class 11) by carcinoma cells in 13 out of 34 (38%) cases. Aberrant expression of HLA class I antigens was frequently observed in cases in which MAGE genes and p53 overexpression were detected. The altered expression of these immunomodulatory molecules in HNSCC may affect prognosis and has important implications for peptide-based immunotherapy strategies for these patients.

show abstract

Section: Discussioncontrasting

confidence: 98%

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma

Vora

Rodgers²,

Aj³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Immunohistochemical staining of frozen and/or formalin-fixed, paraffin-embedded HNSCC primary lesions has detected HLA class I antigen loss and downregulation with a frequency ranging from 6 to 81% (14)(15)(16)(17)(18)(19)(20)(21) information is available on the role of TAP1, TAP2 and tapasin defects in the generation of the abnormal HLA class I antigen phenotypes identified in HNSCC lesions. The lack of this information has a negative impact on the design of strategies to correct HLA class I antigen defects in HNSCC lesions.…”

Section: Introductionmentioning

confidence: 99%

HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis

Bandoh¹

2010

Oncol Rep

View full text Add to dashboard Cite

Abstract. HLA class I antigen processing machinery plays a crucial role in the generation of peptides from endogeneously synthesized proteins and in their presentation to cytotoxic T lymphocytes. The purpose of this study was to analyze the downregulation of HLA class I antigen, transporter associated with antigen processing (TAP) and tapasin in primary and metastatic lesions of head and neck squamous cell carcinoma (HNSCC) and to compare TAP, tapasin and HLA class I antigen downregulation in metastatic lesions with that of primary lesions. We analyzed expression levels of TAP1, TAP2, tapasin and HLA class I antigen in 25 primary and autologous metastatic lesions by staining formalin-fixed, paraffin-embedded tissue sections in the immunoperoxidase reaction. We identified the expression levels of TAP1, TAP2, tapasin and HLA class I antigen were coordinately downregulated in both primary and metastatic lesions and were significantly lower in metastatic lesions than in autologous primary lesions tested. HLA class I antigen downregulation in metastatic lesion was significantly associated with reduced disease-free survival of patients (P<0.05). Multivariate Cox proportional hazards model analysis identified negativity of HLA class I antigen as an independent prognostic marker. HLA class I antigen and TAP are likely to be downregulated in metastatic lesions compared with primary lesions in HNSCC. The higher frequency of HLA class I antigen and TAP downregulation in metastases play a role in the clinical course of the disease.

show abstract

“…However, two drawbacks have to be considered: (1) As yet, we were not able to obtain tumor cell suspensions from SCHNC that routinely meet the requirements for vaccine prepara tion, in particular relating to total viable cell yield and purity. (2) As ASI involves MHCrestricted mechanisms of immune recogni tion and host defence, the irregular pattern of HLA expression on tumor cells may give rise to escape mechanisms [3,12,19,26], Nevertheless, ASI remains a very promis ing approach for antimetastatic treatment since ultimately, no second therapy is of sim ilar specificity.…”

Section: Discussionmentioning

confidence: 99%

Postoperative Active-Specific Immunotherapy of Lymph Node Micrometastasis in a Guinea Pig Tumor Model

Bier¹,

Armonat²,

Bier

et al. 1989

ORL

View full text Add to dashboard Cite

Strain 2 guinea pigs bearing the transplanted intradermally growing line 10 tumor underwent surgical tumor excision at a time when the tumor had already metastasized to the first draining lymph node. Postoperative active-specific immunotherapy (ASI) consisted of two vaccinations with either Newcastle disease virus (NDV) modified or BCG-admixed line 10 tumor cells. 32% of the animals were cured of residual lymphatic micro-metastasis by ASI with NDV-modified tumor cells while ASI with BCG was successful in 45%. No synergistic effect was observed when both ASI procedures were combined. Vaccine preparations with mitomycin C inactivated tumor cells proved to be less (NDV) or noneffective (BCG) compared to those with irradiated tumor cells.

show abstract

HLA Class I and Class II Antigen Expression on Squamous Cell Carcinoma of the Head and Neck

Cited by 31 publications

References 18 publications

An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma

An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma

HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis

Postoperative Active-Specific Immunotherapy of Lymph Node Micrometastasis in a Guinea Pig Tumor Model

Contact Info

Product

Resources

About